Selected research
Industry Research
Medications for Alcohol Use Disorder (AUD) Industry Research Report 2026
Market perspective
The global Medications for Alcohol Use Disorder (AUD) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Medications for Alcohol Use Disorder (AUD) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Medications for Alcohol Use Disorder (AUD) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Medications for Alcohol Use Disorder (AUD) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Medications for Alcohol Use Disorder (AUD) include Teva, Sun Pharmaceutical Industries, Merck KGaA, Mylan, Beijing Wellso Pharmaceutical Co, Zydus Pharmaceuticals, Taj Pharmaceuticals, TAGI Pharma Inc. and Rusan Pharma Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Medications for Alcohol Use Disorder (AUD) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Medications for Alcohol Use Disorder (AUD).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medications for Alcohol Use Disorder (AUD) Market by Company
Teva
Sun Pharmaceutical Industries
Merck KGaA
Mylan
Beijing Wellso Pharmaceutical Co
Zydus Pharmaceuticals
Taj Pharmaceuticals
TAGI Pharma Inc.
Rusan Pharma Ltd
Lundbeck
Glenmark Pharmaceuticals
Alvogen
Alkermes
Medications for Alcohol Use Disorder (AUD) Segment by Type
Acamprosate
Naltrexone
Disulfiram
Other
Medications for Alcohol Use Disorder (AUD) Segment by Application
Hospital
Rehabilitation Institutions
Others
Medications for Alcohol Use Disorder (AUD) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Alcohol Use Disorder (AUD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medications for Alcohol Use Disorder (AUD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Alcohol Use Disorder (AUD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Medications for Alcohol Use Disorder (AUD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Acamprosate
- Naltrexone
- Disulfiram
- Other
Applications
- Hospital
- Rehabilitation Institutions
- Others
Companies covered
- Teva
- Sun Pharmaceutical Industries
- Merck KGaA
- Mylan
- Beijing Wellso Pharmaceutical Co
- Zydus Pharmaceuticals
- Taj Pharmaceuticals
- TAGI Pharma Inc.
- Rusan Pharma Ltd
- Lundbeck
- Glenmark Pharmaceuticals
- Alvogen
- Alkermes
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Medications for Alcohol Use Disorder (AUD) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Acamprosate
- 2.2.3 Naltrexone
- 2.2.4 Disulfiram
- 2.2.5 Other
- 2.3 Medications for Alcohol Use Disorder (AUD) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Rehabilitation Institutions
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Medications for Alcohol Use Disorder (AUD) Breakdown Data by Type
- 3.1 Global Medications for Alcohol Use Disorder (AUD) Historic Market Size by Type (2021-2026)
- 3.2 Global Medications for Alcohol Use Disorder (AUD) Forecasted Market Size by Type (2027-2032)
4 Medications for Alcohol Use Disorder (AUD) Breakdown Data by Application
- 4.1 Global Medications for Alcohol Use Disorder (AUD) Historic Market Size by Application (2021-2026)
- 4.2 Global Medications for Alcohol Use Disorder (AUD) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Medications for Alcohol Use Disorder (AUD) Market Perspective (2021-2032)
- 5.2 Global Medications for Alcohol Use Disorder (AUD) Growth Trends by Region
- 5.2.1 Global Medications for Alcohol Use Disorder (AUD) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Medications for Alcohol Use Disorder (AUD) Historic Market Size by Region (2021-2026)
- 5.2.3 Medications for Alcohol Use Disorder (AUD) Forecasted Market Size by Region (2027-2032)
- 5.3 Medications for Alcohol Use Disorder (AUD) Market Dynamics
- 5.3.1 Medications for Alcohol Use Disorder (AUD) Industry Trends
- 5.3.2 Medications for Alcohol Use Disorder (AUD) Market Drivers
- 5.3.3 Medications for Alcohol Use Disorder (AUD) Market Challenges
- 5.3.4 Medications for Alcohol Use Disorder (AUD) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Medications for Alcohol Use Disorder (AUD) Players by Revenue
- 6.1.1 Global Top Medications for Alcohol Use Disorder (AUD) Players by Revenue (2021-2026)
- 6.1.2 Global Medications for Alcohol Use Disorder (AUD) Revenue Market Share by Players (2021-2026)
- 6.2 Global Medications for Alcohol Use Disorder (AUD) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Medications for Alcohol Use Disorder (AUD) Head Office and Area Served
- 6.4 Global Medications for Alcohol Use Disorder (AUD) Players, Product Type & Application
- 6.5 Global Medications for Alcohol Use Disorder (AUD) Manufacturers Established Date
- 6.6 Global Medications for Alcohol Use Disorder (AUD) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
- 7.2 North America Medications for Alcohol Use Disorder (AUD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Medications for Alcohol Use Disorder (AUD) Market Size by Country (2021-2026)
- 7.4 North America Medications for Alcohol Use Disorder (AUD) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
- 8.2 Europe Medications for Alcohol Use Disorder (AUD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Medications for Alcohol Use Disorder (AUD) Market Size by Country (2021-2026)
- 8.4 Europe Medications for Alcohol Use Disorder (AUD) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
- 9.2 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Medications for Alcohol Use Disorder (AUD) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
- 10.2 South America Medications for Alcohol Use Disorder (AUD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Medications for Alcohol Use Disorder (AUD) Market Size by Country (2021-2026)
- 10.4 South America Medications for Alcohol Use Disorder (AUD) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Market Size (2021-2032)
- 11.2 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Medications for Alcohol Use Disorder (AUD) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.1.4 Teva Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Sun Pharmaceutical Industries
- 12.2.1 Sun Pharmaceutical Industries Company Information
- 12.2.2 Sun Pharmaceutical Industries Business Overview
- 12.2.3 Sun Pharmaceutical Industries Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.2.4 Sun Pharmaceutical Industries Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.2.5 Sun Pharmaceutical Industries Recent Developments
- 12.3 Merck KGaA
- 12.3.1 Merck KGaA Company Information
- 12.3.2 Merck KGaA Business Overview
- 12.3.3 Merck KGaA Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.3.4 Merck KGaA Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.3.5 Merck KGaA Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.4.4 Mylan Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Beijing Wellso Pharmaceutical Co
- 12.5.1 Beijing Wellso Pharmaceutical Co Company Information
- 12.5.2 Beijing Wellso Pharmaceutical Co Business Overview
- 12.5.3 Beijing Wellso Pharmaceutical Co Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.5.4 Beijing Wellso Pharmaceutical Co Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.5.5 Beijing Wellso Pharmaceutical Co Recent Developments
- 12.6 Zydus Pharmaceuticals
- 12.6.1 Zydus Pharmaceuticals Company Information
- 12.6.2 Zydus Pharmaceuticals Business Overview
- 12.6.3 Zydus Pharmaceuticals Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.6.4 Zydus Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.6.5 Zydus Pharmaceuticals Recent Developments
- 12.7 Taj Pharmaceuticals
- 12.7.1 Taj Pharmaceuticals Company Information
- 12.7.2 Taj Pharmaceuticals Business Overview
- 12.7.3 Taj Pharmaceuticals Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.7.4 Taj Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.7.5 Taj Pharmaceuticals Recent Developments
- 12.8 TAGI Pharma Inc.
- 12.8.1 TAGI Pharma Inc. Company Information
- 12.8.2 TAGI Pharma Inc. Business Overview
- 12.8.3 TAGI Pharma Inc. Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.8.4 TAGI Pharma Inc. Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.8.5 TAGI Pharma Inc. Recent Developments
- 12.9 Rusan Pharma Ltd
- 12.9.1 Rusan Pharma Ltd Company Information
- 12.9.2 Rusan Pharma Ltd Business Overview
- 12.9.3 Rusan Pharma Ltd Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.9.4 Rusan Pharma Ltd Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.9.5 Rusan Pharma Ltd Recent Developments
- 12.10 Lundbeck
- 12.10.1 Lundbeck Company Information
- 12.10.2 Lundbeck Business Overview
- 12.10.3 Lundbeck Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.10.4 Lundbeck Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.10.5 Lundbeck Recent Developments
- 12.11 Glenmark Pharmaceuticals
- 12.11.1 Glenmark Pharmaceuticals Company Information
- 12.11.2 Glenmark Pharmaceuticals Business Overview
- 12.11.3 Glenmark Pharmaceuticals Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.11.4 Glenmark Pharmaceuticals Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.11.5 Glenmark Pharmaceuticals Recent Developments
- 12.12 Alvogen
- 12.12.1 Alvogen Company Information
- 12.12.2 Alvogen Business Overview
- 12.12.3 Alvogen Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.12.4 Alvogen Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.12.5 Alvogen Recent Developments
- 12.13 Alkermes
- 12.13.1 Alkermes Company Information
- 12.13.2 Alkermes Business Overview
- 12.13.3 Alkermes Revenue in Medications for Alcohol Use Disorder (AUD) Business (2021-2026)
- 12.13.4 Alkermes Medications for Alcohol Use Disorder (AUD) Product Portfolio
- 12.13.5 Alkermes Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst